CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas

20Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

CD200 has been recently indicated as a robust marker of well-differentiated neuroendocrine neoplasms. Here, we evaluate its role in differential diagnosis of solid pancreatic neoplasms. We immunostained for CD200 22 solid pseudopapillary neoplasms (SPNs), 8 acinar carcinomas (ACs), 2 pancreatoblastomas (PBs), 138 neuroendocrine tumors (PanNETs), and 48 ductal adenocarcinomas. All SPNs showed strong cytoplasmic and membranous staining for CD200, while only one case of AC had focal positivity. The two PBs showed focal CD200 positivity, mainly located in squamoid nests. The vast majority of PanNETs (96%) showed strong cytoplasmic and membranous staining for CD200, whereas all PDACs were negative. As both PanNETs and SPNs express CD200, it has no role in the differential diagnosis between these two entities.

Cite

CITATION STYLE

APA

Lawlor, R. T., Daprà, V., Girolami, I., Pea, A., Pilati, C., Nottegar, A., … Luchini, C. (2019). CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas. Virchows Archiv, 474(1), 105–109. https://doi.org/10.1007/s00428-018-2437-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free